Autoimmune Features and Management of Chronic Spontaneous Urticaria

Epidemiology of Autoimmune Associations

Approximately 14 % of patients with chronic spontaneous urticaria have thyroid autoimmunity, versus ≈ 6 % in the general population, indicating a significant autoimmune link. (observational cohort data) 1, 2
The remaining cases of chronic spontaneous urticaria are driven by non‑autoimmune mechanisms, including non‑immunologic mast‑cell degranulation, physical triggers, or truly idiopathic pathways. 1, 2

A high IgG‑anti‑thyroid peroxidase (anti‑TPO) / total IgE ratio is the most reliable surrogate marker for Type IIb (non‑histaminergic) autoimmune chronic spontaneous urticaria. 3, 4
Elevated IgG‑anti‑TPO antibody levels alone support an autoimmune pathogenesis in chronic spontaneous urticaria. 4
Failure to achieve control with standard‑dose or up‑dosed H1‑antihistamines strongly suggests a non‑histaminergic autoimmune phenotype. 4

For patients identified as having Type IIb autoimmune CSU (high IgG‑anti‑TPO / IgE ratio), guidelines recommend early transition to cyclosporine rather than prolonged omalizumab trials, because response to antihistamines and omalizumab is poor while cyclosporine shows good efficacy. (expert consensus) 3
Histaminergic (non‑autoimmune) CSU should be managed with stepwise antihistamine up‑dosing, progressing to omalizumab if needed. 4
Non‑histaminergic (autoimmune) CSU warrants earlier use of cyclosporine or omalizumab, with cyclosporine being particularly effective. 4

Autoinflammatory syndromes (e.g., CAPS, Schnitzler syndrome) require treatment with interleukin‑1 inhibitors, not antihistamines or omalizumab. 3
Urticarial vasculitis is distinguished by wheals persisting > 24 hours and skin biopsy showing small‑vessel vasculitis, separating it from ordinary chronic urticaria. 1